ArticleThe Yale journal of biology and medicine2011
Medical reversal: why we must raise the bar before adopting new technologies.
Article in The Yale journal of biology and medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis.JAMA network open · 2024Pooled it
- Defining and Measuring the Affordability of New Medicines: A Systematic Review.PharmacoEconomics · 2017Pooled it
- Article
- Puberty Suppression for Pediatric Gender Dysphoria and the Child's Right to an Open Future.Archives of sexual behavior · 2024Article
- Review
- Low-value care in musculoskeletal health care: Is there a way forward?Pain practice : the official journal of World Institute of Pain · 2022Review
- The evidence base for US joint commission hospital accreditation standards: cross sectional study.BMJ (Clinical research ed.) · 2022Article
- Evaluating Reproducibility and Transparency in Emergency Medicine Publications.The western journal of emergency medicine · 2021Article
- Conclusions and perspectives for the 20th century, part 1: 200 years of discussion.Journal of the Royal Society of Medicine · 2021Article
- Article
- The Zentensivist Manifesto. Defining the Art of Critical Care.ATS scholar · 2020Article
- Exploring Novel Computable Knowledge in Structured Drug Product Labels.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2020Article
- Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.Frontiers in pharmacology · 2020Article
- SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.Frontiers in medicine · 2020Article
- Variation in spend on young mental health across Clinical Commissioning Groups in England: a cross-sectional observational study.BMJ open · 2019Observational
- A Rigorous Evaluation of Methoxyflurane is Needed: Comment on "Methoxyflurane Versus Standard of Care for Acute Trauma-Related Pain in the Emergency Setting: Protocol for a Randomised, Controlled Study in Italy (MEDITA)".Advances in therapy · 2019Article
- Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society.Molecular oncology · 2019Review
- Studying de-implementation in health: an analysis of funded research grants.Implementation science : IS · 2017Article
- Sustainability in Health care by Allocating Resources Effectively (SHARE) 9: conceptualising disinvestment in the local healthcare setting.BMC health services research · 2017Article
- Sustainability in Health care by allocating resources effectively (SHARE) 1: introducing a series of papers reporting an investigation of disinvestment in a local healthcare setting.BMC health services research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medical reversal occurs when a new clinical trial - superior to predecessors by virtue of better controls, design, size, or endpoints - contradicts current clinical practice. In recent years, we have witnessed several instances of medical reversal. Famous examples include the class 1C anti-arrhythmics post-myocardial infarction (contradicted by the CAST trial) or routine stenting for stable coronary disease (contradicted by the COURAGE trial). In this paper, we explore the phenomenon of medical reversal. The causes and consequences are discussed. Conflicts of interest among researchers and an unyielding faith in basic science are explored as root causes of reversal. Reversal harms patients who undergo the contradicted therapy during the years it was in favor and those patients who undergo the therapy in the lag time before a change in medical practice. Most importantly, it creates a loss of faith in the medical system by physicians and patients. The solution to reversal is upfront, randomized clinical trials for new clinical practices and a systematic method to evaluate practices already in existence.
Indexed as
Identifiers
22180684PMC3238324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.